Category Archives: Jim’s Corner

One of the impediments to a reasonable public dialogue regarding the creation of a pathway for the approval of biosimilars has been the deluge of misinformation.  It is difficult to choose where to begin in correcting the numerous falsehoods in a recent guest editorial in the New York Times (“Biologics Boondoggle”; 3/8/10). To start, the authors claim that the provisions in the House and Senate health care reform bills would “discourage the development and significantly Read More >

In its 30-year history, biotechnology has made dramatic advances possible in health care, agriculture, energy production and industrial bioprocessing. These accomplishments are the result of painstaking work by many smart people devoted to transforming bench-scale life-science research into commercial products. In economic times both strong and weak this industry thrives. The industry and the promise of its science were tested during the recent and continuing recession. Many biotech companies were forced to downsize or even Read More >